Aclaris Therapeutics
ACRS · Nasdaq · United States
Share price · ACRS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ACRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 8 Oct 2026+11.5%
Nothing announced by ACRS that day or the session before.
- 7 Oct 2026-8.1%
Nothing announced by ACRS that day or the session before.
- 6 Oct 2026-13.3%
Nothing announced by ACRS that day or the session before.
- 1 Oct 2026-16.2%
Nothing announced by ACRS that day or the session before.
- 9 Sep 2026-8.3%
Nothing announced by ACRS that day or the session before.
- 18 Aug 2026+6.5%
Nothing announced by ACRS that day or the session before.
- 3 Aug 2026+6.3%
Nothing announced by ACRS that day or the session before.
- 2 Jun 2026+6.7%
Nothing announced by ACRS that day or the session before.
- 20 Jan 2026+69.1%
Nothing announced by ACRS that day or the session before.
- 8 Dec 2025+12.3%
Nothing announced by ACRS that day or the session before.
Share of unusual movement by asset
For each asset, the share of ACRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(4 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | TSLPMonoclonal antibody | Atopic Dermatitis | |
LepzacitinibNo recent activity | Phase 2 | JAK1/JAK3Small molecule | Atopic Dermatitis |
| Phase 2 | ITK and JAK3Small molecule | Atopic Dermatitis | |
| Preclinical / Unstaged | IL-4Rα and TSLPMultispecific antibody | Atopic Dermatitis |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
March 2029 (1)
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $1.5M | $16M | $20M+ $94M short-term inv. | $19M-$24M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.6M | $18M | $19M+ $72M short-term inv. | $22M-$20M operating cash flow | report ↗ |
| 2026-Q1 | $2.0M | $16M | $191M | $20M | report ↗ |
| 2025-Q3 | $3.3M | $13M | $25M+ $71M short-term inv. | $15M-$11M operating cash flow | report ↗ |
| 2025-Q2 | $1.8M | $11M | $25M+ $74M short-term inv. | $15M-$10.0M operating cash flow | report ↗ |
| 2025-Q1 | $1.5M | $12M | $30M+ $75M short-term inv. | $15M-$13M operating cash flow | report ↗ |
| 2024-Q3 | $4.3M | $6.0M | $48M+ $80M short-term inv. | $7.6M$22M operating cash flow | report ↗ |
| 2024-Q2 | $2.8M | $8.8M | $23M+ $88M short-term inv. | $11M-$12M operating cash flow | report ↗ |
| 2024-Q1 | $2.4M | $9.8M | $36M+ $92M short-term inv. | $17M-$21M operating cash flow | report ↗ |
| 2023-Q3 | $9.3M | $24M | $39M+ $64M short-term inv. | $29M-$25M operating cash flow | report ↗ |
| 2023-Q2 | $1.9M | $25M | $31M+ $89M short-term inv. | $30M-$21M operating cash flow | report ↗ |
| 2023-Q1 | $2.5M | $23M | $45M+ $126M short-term inv. | $28M-$26M operating cash flow | report ↗ |
| 2022-Q3 | $19M | $24M | $62M+ $186M short-term inv. | $20M-$7.8M operating cash flow | report ↗ |
| 2022-Q2 | $1.5M | $19M | $68M+ $180M short-term inv. | $21M-$20M operating cash flow | report ↗ |
| 2022-Q1 | $1.4M | $14M | $36M+ $143M short-term inv. | $19M-$21M operating cash flow | report ↗ |
| 2021-Q3 | $1.7M | $14M | $54M+ $144M short-term inv. | $21M-$11M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $7.8M | $53M | $20M+ $71M short-term inv. | $16M-$47M operating cash flow | report ↗ |
Aclaris reported full-year 2025 revenue of $7.83M, down 58.2% YoY, and R&D spend of $52.65M, up 56.7% YoY. Cash and equivalents were $19.96M, while cash, cash equivalents and marketable securities totaled $151.4M. The full-year net loss was $64.92M, with basic and diluted net loss per share of $0.53.
Management said existing cash, cash equivalents and marketable securities are expected to fund operations into the second half of 2028, excluding potential business development, financing, or planned Phase 2b trial costs. Clinical updates included positive interim Phase 1a SAD/MAD results for ATI-052, with complete top-line results expected in the second quarter of 2026 and Phase 1b proof-of-concept trials in atopic dermatitis and asthma underway; a Phase 2b program is planned for the second half of 2026. The company also expects top-line results from the bosakitug Phase 2 trial in atopic dermatitis in the second half of 2026, plans to file an IND for ATI-9494 in the second half of 2026, and reported that ATI-2138 demonstrated 93% mean hair regrowth in a murine alopecia model.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $19M | $34M | $25M+ $89M short-term inv. | $33M-$20M operating cash flow | report ↗ |
| 2023-FY | $31M | $98M | $40M+ $79M short-term inv. | $22M-$78M operating cash flow | report ↗ |
| 2022-FY | $30M | $78M | $45M+ $172M short-term inv. | $22M-$68M operating cash flow | report ↗ |
| 2021-FY | $6.8M | $44M | $27M+ $164M short-term inv. | $23M-$52M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($1.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-01 | Kolbeck Roland Wilhelm · Chief Scientific Officer | Option exercise | 36,375 | — | — | Form 4 |
| 2026-08-01 | Kolbeck Roland Wilhelm · Chief Scientific Officer | Tax withholding | 12,385 | $5.20 | $64K | Form 4 |
| 2026-08-01 | Kolbeck Roland Wilhelm · Chief Scientific Officer | Option exercise (derivative) | 36,375 | — | — | Form 4 |
| 2026-06-05 | GOWEN MAXINE · director | Option exercise | 11,580 | — | — | Form 4 |
| 2026-06-05 | MILANO VINCENT · director | Option exercise | 11,580 | — | — | Form 4 |
| 2026-06-05 | Molineaux Christopher P. · director | Option exercise | 11,580 | — | — | Form 4 |
| 2026-06-05 | Humphries William D. · director | Option exercise | 11,580 | — | — | Form 4 |
| 2026-06-05 | SCHIFF ANDREW N · director | Option exercise | 11,580 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 136 reporting institutions held 110.5M shares ($406.2M, 69.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BML Capital Management, LLC | 14,250,000 | $53.4M |
| 2 | Deep Track Capital, LP | 9,345,000 | $35.0M |
| 3 | BlackRock, Inc. | 7,407,065 | $27.8M |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 6,804,072 | $25.5M |
| 5 | Vivo Capital, LLC | 6,666,666 | $25.0M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 5,167,469 | $19.4M |
| 7 | Frazier Life Sciences Management, L.P. | 4,925,374 | $18.5M |
| 8 | Rock Springs Capital Management LP | 4,472,650 | $16.8M |
| 9 | Decheng Capital LLC | 4,041,736 | $15.2M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 3,871,000 | $14.5M |
| 11 | Balyasny Asset Management L.P. | 3,361,328 | $12.6M |
| 12 | Kalehua Capital Management LLC | 3,169,921 | $11.9M |
| 13 | MORGAN STANLEY | 2,746,302 | $10.3M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2,423,691 | $9.1M |
| 15 | CITADEL ADVISORS LLC | 2,249,319 | $8.4M |